# US 2026/0092327 A1 · Methods of monitoring mutations in treatment of colorectal cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092327 A1
- Document ID: US20260092327A1
- Status: Published application
- Kind: A1
- Application number: 19/109,436
- Filed: 2023-09-08
- Published: 2026-04-02
- Earliest claimed: 2022-09-08
- Assignees: Cardiff Oncology, Inc.
- Applicants: Cardiff Oncology, Inc.
- Inventors: Maya Ridinger; Errin Samuelsz; Tod Smeal
- Web page: https://patentgrep.com/patent/US20260092327A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 31/4425: Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07K 16/22: against growth factors {; against growth regulators}
- G01N 33/57535: of the large intestine, e.g. colon, rectum or anus
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided includes methods, compositions and kits for improving outcome of a treatment for colorectal cancer, and methods, compositions and kits for determining responsiveness of a subject to a treatment for colorectal cancer. Determining responsiveness can comprise determining change(s) in mean level of somatic mutations of at least three genes in the subject. The treatment for colorectal cancer can comprise administering PLK1 inhibitor (e.g., onvansertib) and bevacizumab to the subject.

## Claims

### Claim 1

A method of predicting or determining responsiveness of a subject to a treatment for colorectal cancer, comprising:
treating the subject with colorectal cancer, wherein the treatment for colorectal cancer comprises administering a PLK1 inhibitor and bevacizumab to the subject;
detecting change(s) in mean level of somatic mutations of at least three genes in the subject, wherein the at least three genes comprise KRAS, APC and TP53 genes; and
determining the responsiveness of the subject to the treatment for colorectal cancer based on the detected change(s) in mean level of somatic mutations.

### Claim 2 (depends on 1)

The method of claim 1, wherein the treatment for colorectal cancer further comprises administering a chemotherapy to the subject.

### Claim 3 (depends on 1)

The method of claim 1, wherein the at least three genes further comprise one or more genes selected from the group consisting of AKT1, ALK, AR, ARAF, AR/01A, ATM, BRAF, BRCA1, BRCA2, CCND1, CCND2, CCNE1, COH1, CDK4, CDK6, CDK12, COKN2A, CTNNB1, DDR2, EGFR, ERBB2, ESR1, EZH2, FBXW1, FGFR1, FGFR2, FGFR3, G4TA3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KIT, MAP2K1, MAP2K2, MAPK1, MAPK3, MET, MLH1, MPL, MTOR, MYC, NF1, NFE2L2, NOTCH1, NPM1, NRAS, NTRK1, NTRK3, POGFRA, PIK3CA, PTEN, PTPN11, RAF1, RB1, RET, RHEB, RHOA, RIT1, ROS1, SMA04, SMO, STK11, TERT, TSC1, and VHL.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the at least three genes further comprise one or more genes selected from the group consisting of AR, BRAF, CCND1, CCND2, CCNE1, COK4, COK6, EGFR, ERBB2, FGFR1, FGFR2, KIT, MET, MYC, POGFRA, PIK3CA, and RAF1.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the at least three genes further comprise one or more genes selected from the group consisting of ALK, FGFR2, FGFR3, NTRK1, RET, and ROS1.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the at least three genes further comprise one or more genes selected from the group consisting of APC, AR, ATM, BRAF, BRCA1, BRCA2, CDK4, CDK6, CDK12, EGFR, ERBB2, HRAS, KIT, KRAS, MAPK1, MAPK3, MET, MYC, NRAS, PIK3CA, PTEN, RB1, STK11, and TP53.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the somatic mutation is a substitution, an insertion, a deletion, an amplification, a fusion or a combination thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the somatic mutation is a point mutation, optionally wherein the point mutation is a single-nucleotide variant (SNV) or a multi-nucleotide variant (MNV).

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the somatic mutation is an insertion-deletion mutation (indel).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein detecting change(s) in the mean level of somatic mutations of the at least three genes in the subject comprises detecting one or more somatic mutations of the at least three genes in the subject (1) during the subject is treated for cancer, (2) before the subject is treated for cancer, (3) after the subject is treated for cancer, or a combination thereof.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein detecting change(s) in the mean level of somatic mutations of the at least three genes in the subject comprises detecting one or more somatic mutations of the at least three genes two or more times in the subject, and optionally at least two of the two or more times occur within 5, 7, 14, 28, 35 or 42 days.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein change(s) in the mean level of somatic mutations of the at least three genes comprises (1) change(s) in the mean level of somatic mutations of the at least three genes during the subject is treated for cancer, (2) change(s) in the mean level of somatic mutations of the at least three genes from before the subject is treated for cancer to during the subject is treated for cancer, or a combination thereof.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, wherein detecting change(s) in the mean level of somatic mutations of at least three genes comprises detecting mean variant allele frequency (VAF) of the at least three genes, optionally wherein the mean variant allele frequency (VAF) is mean mutant allelic frequency (MAF).

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein change(s) in the mean level of somatic mutations of at least three genes is a ratio of mean MAF of at least one additional time point to a first time point, and wherein the first time point is earlier than the at least one additional time point.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein detecting change(s) in the mean level of somatic mutations of the at least three genes in the subject comprises detecting change(s) in the mean level of somatic mutations of the at least three genes in a biological sample from the subject, or derivative thereof.

### Claim 16 (depends on 15)

The method of claim 15, wherein the biological sample comprises a bodily fluid, whole blood, plasma, one or more tissues, one or more cells, or a combination thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the bodily fluid comprises blood, plasma, urine, or a combination thereof, optionally wherein the bodily fluid is blood.

### Claim 18 (depends on 15, 16, 17)

The method of any one of claims 15-17, wherein the biological sample comprises circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), circulating tumor cell (CTC), or a combination thereof.

### Claim 19 (depends on 18)

The method of claim 18, further comprising analyzing the ctDNA using polymerase chain reaction (PCR) or next generation sequencing (NGS), optionally wherein the NGS is a high-throughput NGS and/or wherein the PCR is digital droplet PCR (ddPCR).

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the subject has one or more somatic mutations in the at least three genes before being treated with the PLK1 inhibitor.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein detecting change(s) in the mean level of the somatic mutation(s) of the at least three genes in the subject comprises detecting one or more somatic mutations of the at least three genes emerged in the subject after the subject being treated with the PLK1 inhibitor and bevacizumab.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein determining the responsiveness of the subject comprises determining if the subject is a responder of the treatment, if the subject is or is going to be in complete recover (CR), or if the subject is or is going to be in partial remission (PR).

### Claim 23 (depends on 22)

The method of claim 22, wherein the change in the mean level of the somatic mutation(s) of the at least three genes in the responder is a decrease of at least 50%, at least 75%, at least 90%, at least 95%, or at least 99%, optionally wherein the change in the mean level of the somatic mutations of the at least three genes in the responder is a decrease of at least 99%.

### Claim 24 (depends on 22, 23)

The method of claim 22 or 23, wherein the change in the mean level of the somatic mutations of the at least three genes identifies the responders more accurately relative to change(s) in mutation(s) of one gene, optionally wherein the one gene is KRAS.

### Claim 25 (depends on 22, 23, 24)

The method of anyone of claims 22-24, wherein a specificity and/or an accuracy of identifying responders using the change in the mean level of the somatic mutations of the at least three genes is at least 3%, at least 5%, at least 7%, at least 10%, at least 15%, or at least 20% higher, relative to using change(s) in mutation(s) of one gene, optionally wherein the one gene is KRAS.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any one of claims 1-25, wherein determining the responsiveness of the subject comprises determining progression-free survival (PFS) of the subject.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The method of any one of claims 1-26, wherein determining the responsiveness of the subject comprises determining overall survival (OS).

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein determining the responsiveness of the subject comprises determining if the subject has a partial response to the treatment, if the subject has a complete response to the treatment, if the subject has a stable disease (SD) status, or if the subject has a progressive disease (PD) status.

### Claim 29 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 13-28, wherein the cancer treatment with the PLK1 inhibitor and bevacizumab is maintained if the change in mean MAF of the at least three genes is a decrease of at least 25%, at least 50%, or at least 75%, optionally wherein the decrease is at least 99%, and optionally wherein the decrease is detected at the end of cycle 1 of the cancer treatment or at day 1 of cycle 2 of the cancer treatment.

### Claim 30 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 13-29, wherein the cancer treatment is for at least one week, at least two weeks, at least three weeks, at least one month, at least three months, or at least six months.

### Claim 31 (depends on 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 13-30, wherein the cancer treatment with the PLK1 inhibitor and bevacizumab is modified or discontinued if the change in mean MAF the at least three genes is a decrease of less than 50%, less than 25%, or less than 10%, optionally wherein the decrease is detected at the end of cycle 1 of the cancer treatment or at day 1 of cycle 2 of the cancer treatment.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the cancer treatment with the PLK1 inhibitor and bevacizumab is maintained if mean level of mutations in the at least three genes in the samples decreases to below 0.01% or below 0.001% of mean level of the at least three genes in the sample.

### Claim 33

A method of improving outcome of a treatment for colorectal cancer, comprising:
detecting mean variant allele frequency of a first set of at least three genes in a subject at a first time point in a first sample, wherein the first set of the at least three genes comprise KRAS, APC and TP53 genes, wherein the first time point is before the subject starts the treatment for colorectal cancer, or during the treatment for colorectal cancer, and wherein the treatment for colorectal cancer comprises administering a PLK1 inhibitor and bevacizumab to the subject;
detecting mean variant allele frequency of a second set of at least three gene in the subject at one or more additional time points in one or more additional samples, wherein the second set of the at least three genes comprise KRAS, APC and TP53 genes, and wherein the at least one of the one or more additional time points is during the treatment for colorectal cancer;
determining the difference of the mean variant allele frequency between the first and the one or more additional samples, wherein a decrease in the mean variant allele frequency in at least one of the one or more additional samples relative to the first sample indicates the subject as responsive to the treatment for colorectal cancer; and
continuing the treatment for colorectal cancer to the subject if the subject is indicated as responsive to the treatment for colorectal cancer, or discontinuing the treatment for colorectal cancer to the subject and/or starting a different treatment to the subject if the subject is not indicated as responsive to the treatment for colorectal cancer.

### Claim 34 (depends on 33)

The method of claim 33, wherein the first time point is before the subject starts the treatment for colorectal cancer.

### Claim 35 (depends on 33, 34)

The method of any one of claims 33-34, wherein at least two of the additional time points are during the treatment for colorectal cancer.

### Claim 36

A method of treating colorectal cancer, comprising:
treating a subject with colorectal cancer, wherein the treating comprises administering a PLK1 inhibitor and bevacizumab to the subject;
determining a decrease, relative to a mean variant allele frequency of a first set of at least three genes in a first sample of the subject obtained at a first time point before the subject receives the treatment for colorectal cancer or during the treatment for colorectal cancer, in a mean variant allele frequency of a second set of at least three gene in a second sample of the subject obtained at a second time point after the subject starts receiving the treatment for colorectal cancer; and
continuing with the treatment for colorectal cancer,
wherein the first set of at least three genes and the second set of at least three genes comprise KRAS, APC and TP53 genes.

### Claim 37 (depends on 33, 34, 35, 36)

The method of any one of claims 33-36, wherein the first set of at least three genes detected at the first time point are the same as the second set of at least three genes detected at the second time point.

### Claim 38 (depends on 33, 34, 35, 36)

The method of any one of claims 33-36, wherein the first set of at least three genes detected at the first time point are different from the second set of at least three genes detected at the second time point.

### Claim 39 (depends on 33, 34, 35, 36, 37, 38)

The method of any one of claims 33-38, wherein the first set of at least three genes and/or the second set of at least three genes further comprise one or more genes selected from the group consisting of AKT1, ALK, AR, ARAF, AR/01A, ATM, BRAF, BRCA1, BRCA2, CCND1, CCND2, CCNE1, COH1, CDK4, CDK6, CDK12, COKN2A, CTNNB1, DDR2, EGFR, ERBB2, ESR1, EZH2, FBXW1, FGFR1, FGFR2, FGFR3, G4TA3, GNA11, GNAQ, GNAS, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KIT, MAP2K1, MAP2K2, MAPK1, MAPK3, MET, MLH1, MPL, MTOR, MYC, NF1, NFE2L2, NOTCH1, NPM1, NRAS, NTRK1, NTRK3, POGFRA, PIK3CA, PTEN, PTPN11, RAF1, RB1, RET, RHEB, RHOA, RIT1, ROS1, SMA04, SMO, STK11, TERT, TSC1, and VHL.

### Claim 40 (depends on 33, 34, 35, 36, 37, 38, 39)

The method of any one of claims 33-39, wherein the first set of at least three genes and/or the second set of at least three genes further comprise one or more genes selected from the group consisting of AR, BRAF, CCND1, CCND2, CCNE1, COK4, COK6, EGFR, ERBB2, FGFR1, FGFR2, KIT, MET, MYC, POGFRA, PIK3CA, and RAF1.

### Claim 41 (depends on 33, 34, 35, 36, 37, 38, 39, 40)

The method of any one of claims 33-40, wherein the first set of at least three genes and/or the second set of at least three genes further comprise one or more genes selected from the group consisting of ALK, FGFR2, FGFR3, NTRK1, RET, and ROS1.

### Claim 42 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any one of claims 33-41, wherein the first set of at least three genes and/or the second set of at least three genes further comprise one or more genes selected from the group consisting of APC, AR, ATM, BRAF, BRCA1, BRCA2, CDK4, CDK6, CDK12, EGFR, ERBB2, HRAS, KIT, KRAS, MAPK1, MAPK3, MET, MYC, NRAS, PIK3CA, PTEN, RB1, STK11, and TP53.

### Claim 43 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any one of claims 33-42, wherein the first set of at least three genes and/or the second set of at least three genes have somatic mutation(s); and optionally wherein the somatic mutation is a substitution, an insertion, a deletion, an amplification, a fusion or a combination thereof, optionally wherein the somatic mutation is a point mutation and/or an insertion-deletion mutation (indel), further optionally wherein the point mutation is a single-nucleotide variant (SNV).

### Claim 44 (depends on 43)

The method of claim 43, wherein the somatic mutation(s) in the first set of at least three genes detected at the first time point are the same as the somatic mutation(s) in the second set of at least three genes detected at the second time point.

### Claim 45 (depends on 43)

The method of claim 43, wherein the somatic mutation(s) in the first set of at least three genes detected at the first time point are different from the somatic mutation(s) in the second set of at least three genes detected at the second time point.

### Claim 46 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 33-45, wherein the first time point is prior or immediately prior to the cancer treatment.

### Claim 47 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any one of claims 33-45, wherein the first time point is during the cancer treatment, and optionally at day 5, 7, 14, or 28 of the cancer treatment.

### Claim 48 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 33-47, wherein the one or more additional time points are during the cancer treatment, and optionally on day 5, 7, 14, 28, 35 or 42 of the cancer treatment.

### Claim 49 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 33-48, wherein the first time point and at least one of the one or more additional time points are during the first cycle of the cancer treatment.

### Claim 50 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 33-49, wherein at least one of the one or more additional time points are during the first cycle of the cancer treatment, and at least one of the one or more additional time points are during the second cycle of the cancer treatment.

### Claim 51 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 33-50, wherein the mean variant allele frequency is mean mutant allelic frequency (MAF).

### Claim 52 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 33-51, wherein the detecting step comprises detecting mean variant allele frequency in the first set of at least three genes and/or the second set of at least three genes in a biological sample from the subject, or derivative thereof; optionally wherein the biological sample comprises a bodily fluid, whole blood, plasma, one or more tissues, one or more cells, or a combination thereof, further optionally wherein the bodily fluid comprises blood, plasma, urine, or a combination thereof.

### Claim 53 (depends on 52)

The method of claim 52, wherein the biological sample comprises circulating tumor DNA (ctDNA), circulating tumor cell (CTC), or a combination thereof.

### Claim 54 (depends on 53)

The method of claim 53, comprising analyzing the ctDNA using polymerase chain reaction (PCR) or next generation sequencing (NGS), and optionally wherein the NGS is a high-throughput NGS.

### Claim 55 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 33-54, wherein the subject has one or more mutations in the first set of at least three genes and/or the second set of at least three genes before being treated with the PLK1 inhibitor and bevacizumab.

### Claim 56 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 33-54, wherein the subject does not have mutations in the first set of at least three genes and/or the second set of at least three genes before being treated with the PLK1 inhibitor and bevacizumab.

### Claim 57 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 33-56, wherein the mean variant allele frequency of a second set of at least three gene decreases to below 0.01% or below 0.001% of mean level of the at least three genes in a sample.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 1-57, wherein the subject has received one or more prior cancer treatment.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 1-58, wherein the colorectal cancer is metastatic colorectal cancer.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein the PLK1 inhibitor is onvansertib, BI2536, volasertib (BI 6727), GSK461364, HMN-176, HMN-214, AZD1775, CYC140, rigosertib (ON-01910), MLN0905, TKM-080301, TAK-960, Ro3280, or a combination thereof, optionally wherein the PLK1 inhibitor is onvansertib.

### Claim 61 (depends on 60)

The method of claim 60, wherein the treatment for colorectal cancer comprises administration of onvansertib every day in a cycle of 28 days.

### Claim 62 (depends on 61)

The method of claim 61, wherein the treatment for colorectal cancer comprises administration of onvansertib for the first 21 days and not the last 7 days in a cycle of 28 days.

### Claim 63 (depends on 61)

The method of claim 61, wherein the treatment for colorectal cancer comprises administration of onvansertib for ten days in a cycle of 28 days.

### Claim 64 (depends on 61)

The method of claim 61, wherein the treatment for colorectal cancer comprises administration of onvansertib for five days in the first 14 days and five days in the second 14 days in a cycle of 28 days, optionally wherein the treatment for colorectal cancer comprises administration of onvansertib on days 1-5 and days 15-19 in a cycle of 28 days.

### Claim 65 (depends on 61, 62, 63, 64)

The method of any one of claims 61-64, wherein the treatment comprises administration of onvansertib at 6 mg/m2-24 mg/m2, optionally 6 mg/m2-12 mg/m2 or 12 mg/m2-18 mg/m2, further optionally 12 mg/m2 or 15 mg/m2.

### Claim 66 (depends on 61, 62, 63, 64, 65)

The method of any one of claims 61-65, wherein a maximum concentration (Cmax) of onvansertib in a blood of the subject is from about 100 nmol/L to about 1500 nmol/L.

### Claim 67 (depends on 61, 62, 63, 64, 65, 66)

The method of any one of claims 61-66, wherein an area under curve (AUC) of a plot of a concentration of onvansertib in a blood of the subject over time is from about 1000 nmol/L·hour to about 400000 nmol/L·hour.

### Claim 68 (depends on 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 61-67, wherein a time (Tmax) to reach a maximum concentration of onvansertib in a blood of the subject is from about 1 hour to about 5 hours.

### Claim 69 (depends on 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 61-68, wherein an elimination half-life (T1/2) of onvansertib in a blood of the subject is from about 10 hours to about 60 hours.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any one of claims 1-69, wherein the treatment for colorectal cancer further comprises administering to the subject at least one additional cancer therapeutics or cancer therapy; optionally wherein the PLK inhibitor and the additional cancer therapeutics or cancer therapy are co-administered simultaneously or sequentially.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 1-70, wherein the cancer treatment comprises one or more cycles, and change(s) in the mean level of somatic mutations of the at least three genes or mean variant allele frequency of the first set of at least three genes and/or the second set of at least three genes is detected before, during and/or after each cycle of the cancer treatment.

### Claim 72 (depends on 71)

The method of claim 71, wherein each cycle of treatment is at least 21 days.

### Claim 73 (depends on 71)

The method of claim 71, wherein each cycle of treatment is from about 21 days to about 28 days, optionally 28 days.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 1-73, wherein the subject is human.

### Claim 75 (depends on 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 2-74, wherein the chemotherapy is FOLFIRI, FOLFOX, XELOX (CAPOX), or FOLFOXIRI.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

Use of a PLK1 inhibitor and bevacizumab as a treatment of a subject with colorectal cancer, wherein the responsiveness of the subject to the treatment for colorectal cancer is determined using a method of any one of claims 1-32.

### Claim 77 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

Use of a PLK1 inhibitor and bevacizumab as a treatment of a subject with colorectal cancer, wherein the treatment outcome is improved using a method of any one of claims 33-75.

### Claim 78 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

Use of a PLK1 inhibitor and bevacizumab as a treatment of a subject with colorectal cancer, wherein the subject is treated using a method of any one of claims 33-75.

### Claim 79 (depends on 76, 77, 78)

The use of any one of claims 76-78, wherein the PLK1 inhibitor is onvansertib.
